Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Conditions

• Varicella Zoster

Eligibility Criteria

Sex

ALL

Age

19 Years - 40 Years

Healthy Volunteers

Not accepted

Interventions

• Recombinant Zoster Vaccine — BIOLOGICAL
  After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine

Study Details

This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.

Key Dates

Start date

Mar 18, 2024

Status verified

Mar 2026

Primary completion

Mar 31, 2027

Completion

Sep 30, 2028

Study Design

Enrollment

80 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Arms

• Experimental: Recombinant Zoster Vaccine Administration and Testing
  all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)

Primary Outcome Measure

Adverse Event Reporting [ Time Frame: 30 days-1 year ]

Locations (3)

Find similar trials in Chicago, IL